









Mercado
/
Acciones
/
nasdaq-abbv
/

AbbVie Inc

ABBV

211.960USD

-6.080-2.79%

Cierre 11/03, 16:00（ET）Cotizaciones retrasadas 15 min

374.42BCap. mercado

158.79P/E TTM



AbbVie Inc

211.960

-6.080-2.79%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de AbbVie Inc Compañía

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.

Información de AbbVie Inc



Símbolo de cotizaciónABBV

Nombre de la empresaAbbVie Inc

Fecha de salida a bolsaJan 02, 2013

Director ejecutivoMr. Robert A. Michael, CPA

Número de empleados55000

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 02

Dirección1 N Waukegan Rd

CiudadNORTH CHICAGO

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064

Teléfono18479327900

Sitio Webhttps://www.abbvie.com/

Símbolo de cotizaciónABBV

Fecha de salida a bolsaJan 02, 2013

Director ejecutivoMr. Robert A. Michael, CPA

Ejecutivos de AbbVie Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-77.61%

Ms. Jennifer L. Davis

Independent Director

2.52K

+91.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

Otro

6.16B

39.27%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

11.34B

72.31%

International

3.48B

22.18%

All other countries

603.00M

3.84%

Collaboration revenue

260.00M

1.66%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

Otro

6.16B

39.27%

Estadísticas de accionistas

Actualizado: dom., 17 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Otro

75.93%

Accionistas

Proporción

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Otro

75.93%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.55%

Investment Advisor/Hedge Fund

19.97%

Research Firm

3.07%

Bank and Trust

2.30%

Pension Fund

2.21%

Sovereign Wealth Fund

1.40%

Hedge Fund

1.28%

Insurance Company

0.69%

Family Office

0.20%

Otro

25.33%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

5286

1.32B

74.49%

-7.96M

2025Q2

5271

1.32B

74.93%

+10.38M

2025Q1

5332

1.32B

74.90%

+11.71M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

176.50M

9.99%

+3.35M

+1.94%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

92.10M

5.21%

+1.07M

+1.18%

Jun 30, 2025

State Street Investment Management (US)

80.02M

4.53%

+61.16K

+0.08%

Jun 30, 2025

Geode Capital Management, L.L.C.

39.18M

2.22%

+924.76K

+2.42%

Jun 30, 2025

JP Morgan Asset Management

37.47M

2.12%

+1.87M

+5.24%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

26.78M

1.52%

+1.52M

+6.01%

Jun 30, 2025

Capital Research Global Investors

25.27M

1.43%

-8.24M

-24.60%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

23.51M

1.33%

+254.93K

+1.10%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.65M

1.11%

-1.78M

-8.30%

Jun 30, 2025

ETFs relacionados



Actualizado: dom., 2 de nov

Nombre

Proporción

iShares ESG Aware MSCI USA Value ETF

12.4%

Proshares Ultra Health Care

8.16%

iShares U.S. Healthcare ETF

8.12%

Health Care Select Sector SPDR Fund

8.11%

First Trust NASDAQ Pharmaceuticals ETF

8.08%

JPMorgan Healthcare Leaders ETF

7.39%

Fidelity MSCI Health Care Index ETF

7.06%

Themes US Cash Flow Champions ETF

6.78%

Simplify Health Care ETF

6.75%

iShares Core High Dividend ETF

6.32%

iShares ESG Aware MSCI USA Value ETF

Proporción12.4%

Proshares Ultra Health Care

Proporción8.16%

iShares U.S. Healthcare ETF

Proporción8.12%

Health Care Select Sector SPDR Fund

Proporción8.11%

First Trust NASDAQ Pharmaceuticals ETF

Proporción8.08%

JPMorgan Healthcare Leaders ETF

Proporción7.39%

Fidelity MSCI Health Care Index ETF

Proporción7.06%

Themes US Cash Flow Champions ETF

Proporción6.78%

Simplify Health Care ETF

Proporción6.75%

iShares Core High Dividend ETF

Proporción6.32%

Dividendos



Un total de 48.58B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

